BullFrog AI Holdings Business Summary

BullFrog AI Holdings, Inc. (BFRG) is a digital biopharmaceutical company that generates revenue through a hybrid model of platform licensing, commercial collaborations, and strategic R&D partnerships. Its primary business segments leverage the proprietary bfLEAP™ analytical platform and the bfPREP™ data-harmonization module to identify high-value patient subgroups and optimize clinical trial designs. Key revenue drivers include a global commercial rollout with Sygnature Discovery—projected to generate up to $30 million through 2028—and precision oncology analytics for partners like Eleison Pharmaceuticals. Relative to direct competitors such as Lixte Biotechnology, VistaGen Therapeutics, Apollomics, and Iktos, BullFrog AI distinguishes itself as a "causal AI" specialist, focusing on de-risking late-stage clinical assets through superior data standardization and its recently unveiled scenario-based decision engine. The leadership team is anchored by Founder and CEO Vininder (Vin) Singh, a 25-year biotechnology veteran who previously founded MaxCyte (MXCT) and held senior roles at Thermo Fisher Scientific. Chief Financial Officer Josh Blacher, appointed in late 2024, provides deep capital markets expertise from his tenure at Teva Pharmaceuticals and Columbia Business School. The executive suite is further supported by Chief Information Officer JT Koffenberger and Chief Business Development Officer Praveen Kudithipudi. BullFrog AI’s governance is bolstered by a board of directors including William Enright (CEO of Barinthus Biotherapeutics) and Jason D. Hanson (CEO of enGene), with institutional investment from firms such as Fortem Financial Group, Anson Funds Management, and Renaissance Technologies.